| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CLINICAL RESEARCH |











* University Medical Center Groningen, Internal Medicine, Nephrology, Groningen, The Netherlands;
Leiden University Medical Center, Clinical Epidemiology, Leiden, The Netherlands;
Karolinska Institutet, University Hospital at Huddinge, Department of Renal Medicine, Institution of Molecular Medicine, Stockholm, Sweden;
University Hospital Aachen, Department of Nephrology, Aachen, Germany; || Hans Mak Institute, Naarden, The Netherlands; ¶ Academic Medical Center, Nephrology, Amsterdam, The Netherlands
Correspondence: Friso L.H. Muntinghe, University Medical Center Groningen, Department of Internal Medicine, Hanzeplein 1, PO Box 30001, 9700 RB Groningen, The Netherlands. Phone: 31-50-3616161; Fax: 31-50-3619069; E-mail: f.l.h.muntinghe{at}int.umcg.nl
Received for publication April 28, 2008. Accepted for publication February 21, 2009.
The CC-chemokine receptor 5 (CCR5) is a receptor for various proinflammatory chemokines, and a deletion variant of the CCR5 gene (CCR5
32) leads to deficiency of the receptor. We hypothesized that CCR5
32 modulates inflammation-driven mortality in patients with ESRD. We studied the interaction between CCR5 genotype and levels of high-sensitivity C-reactive protein (hsCRP) in 603 incident dialysis patients from the multicenter, prospective NEtherlands COoperative Study on the Adequacy of Dialysis (NECOSAD) cohort. CCR5 genotype and hsCRP levels were both available for 413 patients. During 5 yr of follow-up, 170 patients died; 87 from cardiovascular causes. Compared with the reference group of patients who had the wild-type CCR5 genotype and hsCRP
10 mg/L (n = 225), those carrying the deletion allele with hsCRP
10 mg/L (n = 55) had similar mortality, and those carrying the wild-type genotype with hsCRP > 10 mg/L (n = 108) had an increased risk for mortality (HR: 1.82; 95% CI: 1.29 to 2.58). However, those carrying the deletion allele with hsCRP > 10 mg/L (n = 25) had a mortality rate similar to the reference group; this seemingly protective effect of the CCR5 deletion was even more pronounced for cardiovascular mortality. We replicated these findings in an independent Swedish cohort of 302 ESRD patients. In conclusion, the CCR5
32 polymorphism attenuates the adverse effects of inflammation on overall and cardiovascular mortality in ESRD.
Related Article
J. Am. Soc. Nephrol. 2009 20: 1429-1431.
This article has been cited by other articles:
![]() |
J. J. Carrero and P. Stenvinkel Persistent Inflammation as a Catalyst for Other Risk Factors in Chronic Kidney Disease: A Hypothesis Proposal Clin. J. Am. Soc. Nephrol., December 1, 2009; 4(Supplement_1): S49 - S55. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Kovesdy and K. Kalantar-Zadeh Do Genes Allow Inflammation to Kill or Not to Kill? J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1429 - 1431. [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673